Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Erleada

Patient speaking to doctor

The outcomes are already chosen. So when can patients really shape them?

Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.

Cuttsy + Cuttsy

- PMLiVE

J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE

Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer

- PMLiVE

Johnson & Johnson announces change in senior leadership role

Tom Cavanaugh has been appointed as Executive Vice President, Worldwide Chairman Innovative Medicine

- PMLiVE

Johnson & Johnson commits $5.5bn to end remaining talc litigation

The resolution comes after plaintiffs were unable to prove that J&J’s talc products caused their ovarian cancer

Woman with headache

It’s time to stop calling adverse events ‘manageable’

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.

Cuttsy + Cuttsy

Man reading pamphlet

Where translation falls short in practice

Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.

Cuttsy + Cuttsy

- PMLiVE

J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis

Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes

- PMLiVE

J&J’s Icotyde approved by US FDA for plaque psoriasis

Plaque psoriasis affects over 125 million people worldwide

Scientist

UK clinical trial regs are changing — here’s what’s happening

Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.

Cuttsy + Cuttsy

- PMLiVE

Atrogi moves forward in phase 1 trial for oral candidate to improve metabolic and muscle health

First-in-class oral therapy mimics the effects of exercise with broad potential as a novel treatment for muscle-sparing weight loss

- PMLiVE

J&J’s nipocalimab gets FDA Fast Track designation for lupus

The autoimmune disease affects approximately three to five million people globally

- PMLiVE

LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus

There are currently no approved treatments specifically indicated for LS in the US or Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links